
Kamari Pharma Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology and the ...
Preclinical results presented demonstrate KM-023 is a highly effective and selective oral TRPV3 inhibitor KM-023 normalized cells proliferation and differentiation in 3D pachyonychia congenita skin model and significantly reduced itch behavior and …